Home | Sitemap | Submit Content | Contact Us   
imageHome : Latest News : Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment ... - News-Medical.Net

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment ... - News-Medical.Net

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service28 times read : Adjust font size: Decrease font Enlarge font
image

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon ...

Read this article...



Post your comment comment Comments (0 posted)

copyright